Everett Harris & Co. CA Sells 1,656 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Everett Harris & Co. CA trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,502 shares of the medical equipment provider’s stock after selling 1,656 shares during the period. Everett Harris & Co. CA’s holdings in Zimmer Biomet were worth $5,609,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. International Assets Investment Management LLC increased its position in shares of Zimmer Biomet by 11,244.9% in the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock worth $8,146,000 after purchasing an additional 66,345 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in Zimmer Biomet by 37.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock valued at $18,981,000 after acquiring an additional 42,539 shares during the last quarter. TD Asset Management Inc grew its position in Zimmer Biomet by 10.1% during the fourth quarter. TD Asset Management Inc now owns 169,595 shares of the medical equipment provider’s stock valued at $20,640,000 after acquiring an additional 15,552 shares during the last quarter. Bank of Nova Scotia grew its position in Zimmer Biomet by 499.0% during the fourth quarter. Bank of Nova Scotia now owns 134,729 shares of the medical equipment provider’s stock valued at $16,397,000 after acquiring an additional 112,237 shares during the last quarter. Finally, Premier Path Wealth Partners LLC bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $1,093,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Up 0.3 %

ZBH stock traded up $0.31 on Thursday, reaching $106.58. The company’s stock had a trading volume of 635,871 shares, compared to its average volume of 1,809,401. The business has a fifty day simple moving average of $114.40 and a two-hundred day simple moving average of $120.95. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $144.13. The firm has a market cap of $21.93 billion, a PE ratio of 23.07, a PEG ratio of 1.91 and a beta of 1.01. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.89 earnings per share. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Wall Street Analyst Weigh In

A number of brokerages have commented on ZBH. Citigroup increased their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Piper Sandler cut shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $140.00 to $115.00 in a research report on Monday. The Goldman Sachs Group initiated coverage on shares of Zimmer Biomet in a research report on Thursday, May 30th. They set a “neutral” rating and a $129.00 price target on the stock. Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Tuesday, May 21st. Finally, Oppenheimer increased their price objective on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $131.76.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.